• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ampio Announces Voluntary Delisting and SEC Deregistration

    3/25/24 5:00:00 PM ET
    $AMPE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPE alert in real time by email

    ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").

    Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

    The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with the Securities and Exchange Commission ("SEC") to effect the delisting and deregistration of its common stock on or about April 4, 2024 and the delisting is expected to become effective on or about April 14, 2024.

    Following the delisting of the Company's common stock from the NYSE American, the Company intends to file a Form 15 with the SEC on or about April 15, 2024 to suspend its reporting obligations under the Act. As a result of the filing of the Form 15, the Company's obligation to file certain Exchange Act reports and forms with the SEC, including Forms 10-K, 10-Q, and 8-K, will cease. Other SEC filing requirements will terminate upon the effectiveness of the deregistration. The Company expects that the deregistration of its common stock will become effective 90 days after the filing of the Form 15 with the SEC. The documents filed with the SEC will be available on the Company's website below.

    The Board made the decision to pursue delisting and deregistration of its common stock following its review and careful consideration of a number of factors, including, but not limited to, the Company's current and likely future non-compliance with the continued listing requirements of the NYSE American that would inevitably result in delisting of the Company's common stock by the NYSE American and the required personnel resources and the high costs relating to Exchange Act and NYSE American disclosure and reporting requirements and related regulatory burdens, which have resulted and would continue to result in significant operating expense.  In light of these factors, the Board has determined that it is in the Company's best interests that the Company take steps designed to ensure sufficient cash to adequately fund an orderly wind down of the Company's operations and to maximize the Company's cash position.

    About Ampio Pharmaceuticals, Inc.

    Ampio Pharmaceuticals, Inc. (NYSE:AMPE) had previously focused on the development of a potential treatment for osteoarthritis as part of its OA-201 program.  The OA-201 development program is exploring Ampio's unique and proprietary small molecule formulation as a potential treatment of osteoarthritis of the knee ("OAK") and other joints. As we announced in February 2024, the pain reduction benefit was not observed in the data from a set of non-clinical studies of OA-201, resulting in the termination of the OA-201 program at that time.

    Caution Regarding Forward-Looking Statements

    All statements other than statements of historical facts contained in this press release, including statements regarding future expectations, plans and prospects for the Company, including but not limited to statements about the expected timing of the delisting from the NYSE American and deregistration of the Company's common stock, the Company's ability to preserve cash in order to adequately fund an orderly wind down of the Company's operations, and the Company's actions to maximize the Company's cash position, are forward-looking statements. Words such as "may", "will", "should", "forecast", "could", "expect", "suggest", "believe", "estimate", "continue", "anticipate", "intend", "ongoing", "opportunity", "potential", "predicts", "seek", "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology, typically identify forward-looking statements.

    Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties including: (i) the ability to retain key personnel in order to pursue the wind down of the Company's operations, cash conservation plan, and resolution of the Company's pending legal proceedings; (ii) our available alternatives are limited and there is no assurance that any alternative will result in any distribution to or cash return to our stockholders; (iii) we plan to initiate steps to exit from certain reporting requirements under the Exchange Act, which will substantially reduce publicly available information about us; (iv) currently pending legal proceedings and any future legal proceedings may adversely affect our cash position and limit our pursuit of strategic options; (v) the settlement in principle of certain legal actions is subject to a number of conditions and risks; (vi) with the Board approval to delist our stock, we expect a negative impact on the price of our stock and the ability to sell our common stock in the public market; and (vii) other important factors that are described in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent periodic reports filed with the SEC.

    We undertake no obligation to update or revise publicly any forward-looking statements to reflect events or circumstances after the date of such statements for any reason, except as otherwise required by law.

    For more information, contact:

    Ampio Pharmaceuticals, Inc.

    Michael A. Martino

    Chief Executive Officer

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-announces-voluntary-delisting-and-sec-deregistration-302098667.html

    SOURCE Ampio Pharmaceuticals, Inc.

    Get the next $AMPE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMPE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ampio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)

      12/7/23 10:20:57 AM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ampio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)

      2/2/23 12:36:29 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ampio Pharmaceuticals Inc.

      SC 13G - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)

      7/8/22 4:57:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Buchi J Kevin

      4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)

      6/13/23 12:07:57 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buchi J Kevin

      4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)

      6/9/23 2:26:37 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Martino Michael A

      4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)

      5/26/23 1:30:43 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Financials

    Live finance-specific insights

    See more
    • Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock

      ENGLEWOOD, Colo., May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 8, 2023. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form.

      5/26/23 4:40:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals, Inc. to Hold Conference Call

      ENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, announced that the Company will be hosting a conference call on April 28, 2022 at 8am EDT regarding the update from the Food and Drug Administration with respect to its AP-013 study.  Conference Call Details Date/Time: April 28, 2022 at 8am EDT Title: Investor Update Call - FDA Response Letter AP-01

      4/27/22 4:45:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call

      ENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST.  Conference Call Details Date/Time: March 29, 2022, at 4:30 pm EST Conferencing Link: https://event.on24.com/wcc/r/3683372/9CD2C8B658E56541C487F44C34E897BBAccess Code:  66744 Canada dial-in number (Toll Free): 1 833 950 0062 Canad

      3/23/22 8:30:00 AM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ampio Pharmaceuticals Inc.

      15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      4/15/24 4:15:06 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Ampio Pharmaceuticals Inc.

      25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      4/4/24 1:32:03 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

      3/25/24 5:25:17 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital resumed coverage on Ampio Pharmaceuticals with a new price target

      Roth Capital resumed coverage of Ampio Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      1/24/21 2:54:22 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

      ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is

      4/3/24 2:33:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Announces Voluntary Delisting and SEC Deregistration

      ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with

      3/25/24 5:00:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ampio Provides Update on Results from Pre-IND Enabling Studies

      ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.  Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce p

      2/14/24 5:45:00 PM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes

      ENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq. to the Company's Board of Directors. The appointment of Ms. Jobes expands the Company's Board of Directors from seven members to eight. "We welcome Elizabeth as an addition to our Board of Directors as we enter into a pivotal period at Ampio," said Mike Martino, Chairman and CEO of Ampio. "Throughout her impress

      2/10/22 9:00:00 AM ET
      $AMPE
      Biotechnology: Pharmaceutical Preparations
      Health Care